Analyst Price Targets — MAZE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 11:12 am | — | Truist Financial | $64.00 | $27.42 | TheFly | Maze Therapeutics price target lowered to $64 from $68 at Truist |
| March 17, 2026 8:06 pm | Danielle Brill | Truist Financial | $68.00 | $50.39 | StreetInsider | Truist Securities Starts Maze Therapeutics (MAZE) at Buy |
| March 10, 2026 8:41 am | — | Mizuho Securities | $97.00 | $51.06 | TheFly | Maze Therapeutics initiated with an Outperform at Mizuho |
| January 19, 2026 5:12 pm | — | BTIG | $46.00 | $40.77 | TheFly | Maze Therapeutics price target raised to $46 from $37 at BTIG |
| December 19, 2025 1:07 pm | Debjit Chattopadhyay | Guggenheim | $46.00 | $41.92 | TheFly | Maze Therapeutics price target raised to $46 from $34 at Guggenheim |
| December 4, 2025 10:32 am | — | Wells Fargo | $55.00 | $41.49 | TheFly | Maze Therapeutics initiated with an Overweight at Wells Fargo |
| December 3, 2025 2:06 pm | — | H.C. Wainwright | $60.00 | $38.75 | TheFly | Maze Therapeutics price target raised to $60 from $50 at H.C. Wainwright |
| November 13, 2025 9:08 pm | — | Raymond James | $48.00 | $31.84 | TheFly | Maze Therapeutics initiated with a Strong Buy at Raymond James |
| September 15, 2025 10:42 am | Debjit Chattopadhyay | Guggenheim | $34.00 | $23.25 | TheFly | Maze Therapeutics price target raised to $34 from $19 at Guggenheim |
| September 2, 2025 10:38 am | — | BTIG | $30.00 | $15.32 | TheFly | Maze Therapeutics initiated with a Buy at BTIG |
Latest News for MAZE
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday,…
BlackRock Inc. purchased a new position in Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,502,841 shares of the company's stock, valued at approximately $104,525,000. BlackRock Inc. owned approximately 6.33% of Maze Therapeutics as
Bank of America Corp DE increased its holdings in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 961.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 195,084 shares of the company's stock after buying an additional 176,703 shares during the period. Bank of America Corp DE
Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces…
ARCH Venture Management LLC bought a new position in shares of Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor bought 4,120,053 shares of the company's stock, valued at approximately $122,983,582,000. Maze Therapeutics accounts for about 11.2% of ARCH Venture Management
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MAZE.
U.S. House Trading
No House trades found for MAZE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.